Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.

ABSTRACT:

Background

The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined with standard XELOX plus bevacizumab as first-line treatment of microsatellite stable/proficient mismatch repair (MSS/pMMR) RAS-mutant metastatic colorectal cancer (mCRC).

Patients and methods

TACTIC CRC-02 was a single-center, single-arm, open-label, phase II trial. Eligible patients had previously untreated, unresectable MSS/pMMR, RAS-mutant mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received intravenous tislelizumab (200 mg/m²), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m²) on day 1, with oral capecitabine (1000 mg/m

SUBMITTER: Liu X 

PROVIDER: S-EPMC12870864 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature